- Home
- PIM vs ENGN Comparison
PIM vs ENGN Comparison
Compare PIM & ENGN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- PIM
- ENGN
- Stock Information
- Founded
- PIM 1988
- ENGN 1999
- Country
- PIM United States
- ENGN Canada
- Employees
- PIM N/A
- ENGN N/A
- Industry
- PIM Finance Companies
- ENGN
- Sector
- PIM Finance
- ENGN
- Exchange
- PIM Nasdaq
- ENGN Nasdaq
- Market Cap
- PIM 160.0M
- ENGN 191.1M
- IPO Year
- PIM N/A
- ENGN N/A
- Fundamental
- Price
- PIM $3.35
- ENGN $3.64
- Analyst Decision
- PIM
- ENGN Buy
- Analyst Count
- PIM 0
- ENGN 7
- Target Price
- PIM N/A
- ENGN $23.29
- AVG Volume (30 Days)
- PIM 57.5K
- ENGN 102.8K
- Earning Date
- PIM 01-01-0001
- ENGN 09-09-2025
- Dividend Yield
- PIM 8.28%
- ENGN N/A
- EPS Growth
- PIM N/A
- ENGN N/A
- EPS
- PIM 0.05
- ENGN N/A
- Revenue
- PIM N/A
- ENGN N/A
- Revenue This Year
- PIM N/A
- ENGN N/A
- Revenue Next Year
- PIM N/A
- ENGN N/A
- P/E Ratio
- PIM $63.80
- ENGN N/A
- Revenue Growth
- PIM N/A
- ENGN N/A
- 52 Week Low
- PIM $2.90
- ENGN $2.65
- 52 Week High
- PIM $3.28
- ENGN $11.00
- Technical
- Relative Strength Index (RSI)
- PIM 54.26
- ENGN 48.82
- Support Level
- PIM $3.32
- ENGN $3.54
- Resistance Level
- PIM $3.38
- ENGN $3.89
- Average True Range (ATR)
- PIM 0.03
- ENGN 0.28
- MACD
- PIM 0.00
- ENGN -0.02
- Stochastic Oscillator
- PIM 66.67
- ENGN 28.57
About PIM Putnam Master Intermediate Income Trust
Putnam Master Intermediate Income Trust is a closed-end fund. Its investment objective is to provide high current income and relative stability of net asset value. The fund pursues its goal by investing in U.S. high-grade, high-yield, and international fixed-income securities with limited maturities. The fund's portfolio includes the United States Government and agency mortgage obligations; mortgage-backed securities; corporate bonds and notes, and foreign government and agency bonds and notes.
About ENGN enGene Holdings Inc.
enGene Holdings Inc is a clinical-stage biotechnology company focused on developing gene therapies to improve the lives of patients. The Company is developing non-viral gene therapies based on its novel and proprietary dually derived chitosan, or DDX, gene delivery platform, which allows localized delivery of multiple gene cargos directly to mucosal tissues and other organs.